News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Active Biotech AB Interim Report Jan-March 2
May 4, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN -- (MARKET WIRE) -- May 04, 2007 -- * Laquinimod - Phase II data presented at the American Academy of Neurology (AAN) conference in Boston.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Funding
Recordati fields $12.4B go-private offer
May 22, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer
May 22, 2026
·
1 min read
·
Nick Paul Taylor
Layoff Tracker
AbbVie, Novartis slash US headcount
May 22, 2026
·
55 min read
·
BioSpace Editorial Staff
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
·
3 min read
·
Tristan Manalac
